Recent advances in endocrine therapy for postmenopausal women with early breast cancer: Implications for treatment and prevention

Annals of Oncology

Volumn 15, Issue 12, 2004, Pages 1738-1747

  Tobias, J S ^a  

^a MIDDLESEX HOSPITAL   (United Kingdom)

Author keywords

Adjuvant; Advanced breast cancer; Aromatase inhibitor; Endocrine; Prevention

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; AROMATASE INHIBITOR; CORTICOSTEROID; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EXEMESTANE; FORMESTANE; FULVESTRANT; GONADORELIN; GOSERELIN; LETROZOLE; MEGESTROL ACETATE; PLACEBO; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TAMOXIFEN CITRATE;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER PREVENTION; CEREBROVASCULAR DISEASE; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; ENDOMETRIUM CANCER; FEMALE; FRACTURE; HIGH RISK POPULATION; HOT FLUSH; HUMAN; MUSCULOSKELETAL DISEASE; NONHUMAN; OSTEOLYSIS; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; SARCOMA; SIDE EFFECT; THROMBOEMBOLISM; VAGINA BLEEDING; VAGINA DISCHARGE; VENOUS THROMBOEMBOLISM;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOPREVENTION; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; FEMALE; HUMANS; MIDDLE AGED; NITRILES; POSTMENOPAUSE; RECEPTORS, ESTROGEN; TAMOXIFEN; TRIAZOLES;

EID: 10944236949     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh485     Document Type: Review

References (67)

1. Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 1896; 2: 104-107.
2. National Comprehensive Cancer Network. Breast Cancer. Clinical Practice Guidelines in Oncology v.1.2004. National Comprehensive Cancer Network [online] 2004; www.nccn.org/physician-gls/F_guidelines.html (15 October 2004, date last accessed).
3. Wolff AC, Davidson NE. Early operable breast cancer. Curr Treat Options Oncol 2000; 1: 210-220.
4. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992; 339: 1-15.
5. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351: 1451-1467.
6. Fisher B, Costantino JP, Wickerham DL et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90: 1371-1388.
7. Bissett D, Davis JA, George WD. Gynaecological monitoring during tamoxifen therapy. Lancet 1994; 344: 1244.
8. Cutuli B, Petit J, Fricker J. Adjuvant tamoxifen in breast cancer treatment in postmenopausal women: occurrence of thromboembolic complications. Oncol Rep 1994; 1: 59-63.
9. Wysowski DK, Honig SF, Beitz J. Uterine sarcoma associated with tamoxifen use. N Engl J Med 2002; 346: 1832-1833.
10. Meier CR, Jick H. Tamoxifen and risk of idiopathic venous thromboembolism. Br J Clin Pharmacol 1998; 45: 608-612.
11. Geisler J, King N, Dowsett M et al. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br J Cancer 1996; 74: 1286-1291.
12. Dowsett M, Jones A, Johnston SR et al. In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer. Clin Cancer Res 1995; 1: 1511-1515.
13. Geisler J, Detre S, Berntsen H et al. Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer. Clin Cancer Res 2001; 7: 1230-1236.
14. Bhatnagar AS, Brodie AM, Long BJ et al. Intracellular aromatase and its relevance to the pharmacological efficacy of aromatase inhibitors. J Steroid Biochem Mol Biol 2001; 76: 199-202.
15. Wells SA Jr, Santen RJ, Lipton A et al. Medical adrenalectomy with aminoglutethimide: clinical studies in postmenopausal patients with metastatic breast carcinoma. Ann Surg 1978; 187: 475-484.
16. Goss PE, Powles TJ, Dowsett M et al. Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: phase II report. Cancer Res 1986; 46: 4823-4826.
17. Freue M, Kjaer M, Boni C et al. Open comparative trial of formestane versus megestrol acetate in postmenopausal patients with advanced breast cancer previously treated with tamoxifen. Breast 2000; 9: 9-16.
18. Buzdar A, Esparza-Guerra L. Anastrozole 'Arimidex' does not impair cortisol or aldosterone synthesis in postmenopausal women with advanced breast cancer. Proc Am Soc Clin Oncol 2001; 20: 52b (Abstr 1954).
19. Evans TR, Di Salle E, Ornati G et al. Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women. Cancer Res 1992; 52: 5933-5939.
20. Bisagni G, Cocconi G, Scaglione F et al. Letrozole, a new oral non-steroidal aromatase inhibitor in treating postmenopausal patients with advanced breast cancer. A pilot study. Ann Oncol 1996; 7: 99-102.
21. Bajetta E, Zilembo N, Dowsett M et al. Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients. Eur J Cancer 1999; 35: 208-213.
22. Buzdar AU, Jonat W, Howell A et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Cancer 1998; 83: 1142-1152.
23. Kaufmann M, Bajetta E, Dirix LY et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol 2000; 18: 1399-1411.
24. Dombernowsky P, Smith I, Falkson G et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998; 16: 453-461.
25. Buzdar A, Douma J, Davidson N et al. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol 2001; 19: 3357-3366.
26. Bonneterre J, Buzdar A, Nabholtz JM et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 2001; 92: 2247-2258.
27. Nabholtz JM, Buzdar A, Pollak M et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000; 18: 3758-3767.
28. Bonneterre J, Thurlimann B, Robertson JF et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 2000; 18: 3748-3757.
29. Mouridsen H, Gershanovich M, Sun Y et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001; 19: 2596-2606.
30. Paridaens R, Therasse P, Dirix L et al. First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts) - a randomised phase III trial of the EORTC Breast Group. Proc Am Soc Clin Oncol 2004; 22: 6 (Abstr 114).
31. Wakeling AE, Dukes M, Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res 1991; 51: 3867-3873.
32. Wakeling AE. Similarities and distinctions in the mode of action of different classes of antioestrogens. Endocr Relat Cancer 2000; 7: 17-28.
33. Howell A, DeFriend DJ, Robertson JF et al. Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer. Br J Cancer 1996; 74: 300-308.
34. Howell A, Robertson JF, Quaresma Albano J et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002; 20: 3396-3403.
35. Osborne CK, Pippen J, Jones SE et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 2002; 20: 3386-3395.
36. Pippen J, Osborne CK, Howell A et al. Fulvestrant (Faslodex) versus anastrozole (Arimidex) for the treatment of advanced breast cancer: a prospective combined survival analysis of two multicenter trials. Breast Cancer Res Treat 2003; 82 (Suppl 1): S101 (Abstr 426).
37. Robertson J, Howell A, Abram P. Fulvestrant versus tamoxifen for the first-line treatment of advanced breast cancer (ABC) in postmenopausal women. Ann Oncol 2002; 13: A1640.
38. Steger G, Bartsch R, Wenzel C. Fulvestrant beyond the second hormonal treatment line in metastatic breast cancer. Proc Am Assoc Cancer Res 2003; 22: 20.
39. ATAC Trialists Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002; 359: 2131-2139.
40. Coombes RC, Bliss JM, Gibson U. The Intergroup Exemestane Study (IES) - design and characteristics. Proc Am Soc Clin Oncol 2002; 21: 44b (Abstr 1986).
41. Ingle JN. Adjuvant endocrine therapy in postmenopausal breast cancer. Clin Cancer Res 2003; 9: 480s-485s.
42. Goss PE, Ingle JN, Martino S et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003; 349: 1793-1802.
43. Boccardo F, Rubagotti A, Amoroso D. Anastrozole appears to be superior to tamoxifen in women already receiving adjuvant tamoxifen treatment. Breast Cancer Res Treat 2003; 82 (Suppl 1): S6-S7. (Abstr 3).
44. Baum M, Buzdar A, Cuzick J et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003; 98: 1802-1810.
45. Howell A. Effect of anastrozole on bone mineral density: 2-year results of the 'Arimidex' (anastrozole), tamoxifen, alone or in combination (ATAC) trial. Breast Cancer Res Treat 2003; 82 (Suppl 1): S27 (Abstr 129).
46. Locker GY, Eastell R. The time course of bone fractures observed in the ATAC ('Arimidex', Tamoxifen, Alone or in Combination) trial. Proc Am Soc Clin Oncol 2003; 22: 25 (Abstr 98).
47. Coombes RC, Hall E, Gibson LJ et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350: 1081-1092.
48. Goss PE. NCIC CTG MA.17. Final analysis of updated data. A placebo-controlled trial of letrozole following tamoxifen as adjuvant therapy in postmenopausal women with early stage breast cancer. [online] http://www.asco.org/ac/1,1003,_12-002511-00_18-0026-00_19-0011301-00_21- 00106,00.asp (22 June 2004, date last accessed).
49. Thürlimann B, Robertson JF, Nabholtz JM et al. Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women. Eur J Cancer 2003; 39: 2310-2317.
50. Dowsett M, Harper-Wynne C, Boeddinghaus I et al. HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. Cancer Res 2001; 61: 8452-8458.
51. Ellis MJ, Coop A, Singh B et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001; 19: 3808-3816.
52. Thurlimann B, Hess D, Koeberle D et al. Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95 - a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Efficacy and Tolerability) trial. Breast Cancer Res Treat 2004; 85: 247-254.
53. Lonning PE, Bajetta E, Murray R et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. J Clin Oncol 2000; 18: 2234-2244.
54. Vergote I, Robertson JF, Kleeberg U et al. Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapy. Breast Cancer Res Treat 2003; 79: 207-211.
55. Perey L, Thurlimann B, Hawle H. Fulvestrant (Faslodex) as hormonal treatment in postmenopausal patients with advanced breast cancer progressing after treatment with tamoxifen and aromatase inhibitors. Breast Cancer Res Treat 2002; 76 (Suppl 1): S72 (Abstr 249).
56. Fisher B, Land S, Mamounas E et al. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the national surgical adjuvant breast and bowel project experience. Semin Oncol 2001; 28: 400-418.
57. Powles T, Eeles R, Ashley S et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998; 352: 98-101.
58. Veronesi U, Maisonneuve P, Costa A et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 1998; 352: 93-97.
59. Cuzick J, Forbes J, Edwards R et al. First results from the International Breast Cancer Intervention Study (IBIS-1): a randomised prevention trial. Lancet 2002; 360: 817-824.
60. Medicines Control Agency. Tamoxifen and venous thromboembolism. Curr Probl Pharmacovigilance 2002; 28: 10.
61. Houghton J, George WD, Cuzick J et al. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet 2003; 362: 95-102.
62. Jubelirer SJ, Crowell EB Jr. The STAR (Study of Tamoxifen and Raloxifene) trial in West Virginia. W V Med J 2000; 96: 602-604.
63. Pappas SG, Jordan VC. Chemoprevention of breast cancer: current and future prospects. Cancer Metastasis Rev 2002; 21: 311-321.
64. Cuzick J. Aromatase inhibitors in prevention - data from the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial and the design of IBIS-II (the second International Breast Cancer Intervention Study). Recent Results Cancer Res 2003; 163: 96-103, 264-266.
65. Di Salle E, Geroni C, Lamparelli MG et al. Chemopreventive effect of the aromatase inactivator exemestane (E) combined with the antiestrogen raloxifene (R) in the dimethylbenzanthracene (DMBA)-induced mammary tumours in rats. Proc Am Soc Clin Oncol 2002; 21: 117a (Abstr 465).
66. Buzdar AU, Robertson JF, Eiermann W, Nabholtz JM. An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane. Cancer 2002; 95: 2006-2016.
67. Winer EP, Hudis C, Burstein HJ et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. J Clin Oncol 2002; 20: 3317-3327.